1. Home
  2. Analysis
  3. Capecitabine
  4. Hyperammonaemia

Capecitabine and Hyperammonaemia - a phase IV clinical study of FDA data

Summary:

Hyperammonaemia is reported as a side effect among people who take Capecitabine (capecitabine), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Oxaliplatin, and have Colon cancer.

The phase IV clinical study analyzes which people have Hyperammonaemia when taking Capecitabine. It is created by eHealthMe based on reports of 59,451 people who have side effects when taking Capecitabine from the FDA, and is updated regularly.

What is Capecitabine?

Capecitabine has active ingredients of capecitabine. eHealthMe is studying from 59,495 Capecitabine users. Check the latest studies of Capecitabine.

What is Hyperammonaemia?

Hyperammonaemia is found to be associated with 397 drugs and 562 conditions by eHealthMe. Check the latest studies of Hyperammonaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

59,451 people reported to have side effects when taking Capecitabine.
Among them, 47 people (0.08%) have Hyperammonaemia.

Could Capecitabine cause Hyperammonaemia?

Among these 47 people:

How long have people been on Capecitabine when they have Hyperammonaemia? *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Hyperammonaemia when taking Capecitabine? *

  • female: 53.49 %
  • male: 46.51 %

What is the age of people who have Hyperammonaemia when taking Capecitabine? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 6.98 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 13.95 %
  • 60+: 79.07 %

What are other drugs people take besides Capecitabine? *

  1. Oxaliplatin: 8 people, 17.02%
  2. Amlodipine: 6 people, 12.77%
  3. Pantoprazole: 5 people, 10.64%
  4. Chlorthalidone: 5 people, 10.64%
  5. Ondansetron: 5 people, 10.64%
  6. Metoprolol Succinate: 5 people, 10.64%
  7. Folate: 4 people, 8.51%
  8. Cisplatin: 3 people, 6.38%
  9. Fluorouracil: 3 people, 6.38%
  10. Carboplatin: 2 people, 4.26%

What are other side effects people have besides Hyperammonaemia? *

  1. Encephalopathy (functioning of the brain is affected by some agent or condition): 12 people, 25.53%
  2. Hepatic Steatosis (fatty liver disease): 10 people, 21.28%
  3. Delirium (wild excitement): 10 people, 21.28%
  4. Confusional State: 9 people, 19.15%
  5. Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 7 people, 14.89%
  6. Weakness: 7 people, 14.89%
  7. Nausea And Vomiting: 6 people, 12.77%
  8. Hyperammonaemic Encephalopathy (excess of ammonia in the blood, disorder or disease of the brain): 6 people, 12.77%
  9. Fatigue (feeling of tiredness): 6 people, 12.77%
  10. Venoocclusive Liver Disease (small veins in the liver are obstructed): 5 people, 10.64%

What are the existing conditions these people have? *

  1. Colon Cancer: 10 people, 21.28%
  2. Metastases To Liver (cancer spreads to liver): 7 people, 14.89%
  3. Pancreatic Carcinoma (pancreatic cancer): 5 people, 10.64%
  4. Nausea (feeling of having an urge to vomit): 5 people, 10.64%
  5. Rectal Cancer (cancer of rectum): 4 people, 8.51%
  6. Rectal Cancer Stage Iv (rectal cancer has been carried through the lymph system to distant parts of the body): 3 people, 6.38%
  7. Breast Cancer: 3 people, 6.38%
  8. Metastases To Bone (cancer spreads to bone): 3 people, 6.38%
  9. Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 4.26%
  10. Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 4.26%

* Approximation only. Some reports may have incomplete information.

Do you take Capecitabine and have Hyperammonaemia?

- Check whether Hyperammonaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Capecitabine:

Hyperammonaemia treatments and more:

How severe was Hyperammonaemia and when was it recovered:

Expand to all the drugs that have ingredients of capecitabine:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Capecitabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperammonaemia:

Browse all the conditions that are associated with Hyperammonaemia:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on capecitabine (the active ingredients of Capecitabine) and Capecitabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.